TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite death and nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac-related hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cardiac-related Emergency Department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Lymphedema progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Anti-Fxa Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal Pressure (cm H2O)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence Comparison of APAP vs. CPAP (% Days Device Used)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence Comparison of APAP vs. CPAP (% Days Device Used >4 Hours)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants completed all study procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Negative Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parenting Sense of Competence Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With an Immune Response to Prostatic Acid Phosphatase (PAP) and/or PA2024
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Participants With Highest Grade, Treatment-related, Immune Response Adverse Events (IRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: International Knee Society score (IKS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Young Adult Drug Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of severe AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood sugar control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipids goal achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Access to healthcare
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in pain of mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with splenomegaly achieving a response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary retention
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With BRAF V600 Mutation Positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Classified Based on Different Types of BRAF V600 Mutation Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distance Spherical Aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Spherical Aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Displacement in distal radius fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Stability in the DRU joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of postoperative residual curarization (PORC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Clinical Improvement at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of maximal inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete hematological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall safety profile of PHA-739358
Endpoint domain: Adverse events/effects
Primary endpoint: Complete, partial, or minor cytogenetic response in bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With iPTH Levels Maintained at Target Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complication incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Flow Mediated Dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from ability to perform activities of daily living (ADL) at two years
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from cognitive function/memory at two years
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from quality of life (QOL) at two years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in overall combined wellness score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of new fat cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Punctate - Von frey (grams)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arm/hand pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Prostate Cancer Progression
Endpoint domain: Mortality/survival
Primary endpoint: Composite of all-cause mortality or unplanned aortic stenosis-related hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Obsessive Compulsive Disorder disease burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Depression disease burden
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Pain disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood routine examination of participants with anaphylactic reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvements in Attention/Executive Domain Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Desaturations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Parathyroid Hormone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: composite score of appropriate processes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean LDL level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Contrast-induced acute kidney injury (CI-AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of CSF immune activation as measured by CSF neopterin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of CSF immune activation as measured by CSF beta-2-microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of CSF immune activation as measured by CSF immunoglobulin G index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospital revisit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hospitalization in the next 3 months after the initial visit
Endpoint domain: Mortality/survival
Primary endpoint: Average total outpatient cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Achieved Stem Cell Engraftment After Hematopoietic Stem Cell Transplant (HSCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in TWSTRS - Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial blood oxygenation at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: arterial blood oxygenation at exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients achieving Hb rise 3 gm or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ecarin clotting time (ECT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decreased Need for Systemic Antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in lipoproteins' metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From 0 to t Hours (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative immunoprofile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of uric acid excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fractional uric acid excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum delta effective uric acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta area under the serum uric acid concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Handling of Mepitel® One in acute wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Innate and adaptive immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Future occurrence of acute diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: Future occurrence of ARI
Endpoint domain: Adverse events/effects
Primary endpoint: Future occurrence of impetigo
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration versus time curve 0-24 hours for rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Bleed Rate (ABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified melasma area and severity index (mMASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in muscle cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle pennation angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cmin and Cmax of budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Area Under the Plasma Concentration-time Curve for 24 Hours (AUC24avg) for Rifabutin (RIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of RIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Plasma Concentration (Cmin) of RIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI responses to high-sugar food tastes and food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End of Study Patient Blood Pressure - Within Target Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End of Study Patient Blood Pressure - Outside of Target Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transplacentally transferred antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibodies transferred through breast milk (convalescent mothers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibodies transferred through breast milk (vaccinated mothers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hemostatic Success at 3 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mental health related quality of life (SF-36 questionnaire mental scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Newborn birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycine and D-Serine levels in the plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acrophobia Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weekly Anxiety Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants suffering from urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in activation of pre-supplementary motor area/dorsal anterior cingulate cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: onset of depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binge items related to depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved PMS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Maximum Voluntary Contraction Force (MVCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Imitation skills ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Joint-attention skills ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Turn-taking skills ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri operative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in absolute cerebral oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fruit and vegetable consumption, servings per week
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Soft tissue changes around implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Who Completed the Survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain on the pain subscale of WOMAC index (WOMAC-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral levothyroxine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Development of Deep Vein Thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration Adjusted by Dose (Cmax/D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale (mRS) at 90 Days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of dialysis session with dysfunctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Whole lung deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Content validity of the Reintegration to Normal Living Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Sick Days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement in MADRS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in PHQ-9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse events (AE)/serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent episode of BV
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hepatic lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in 6-minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant findings in EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average errors of coordinates in three planes of space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fall of forced expiratory volume (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Children's Yale-Brown Obsessive-Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants Experiencing ≥1 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing ≥1 Dose-Limiting Toxicity (DLT) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Television viewing at follow up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in creatinine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in myostatin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate after surgical treatment of tumour
Endpoint domain: Mortality/survival
Primary endpoint: Extent of inhibition of ERK phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serious Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Unexpected Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects not requiring rescue anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Women Who Achieve Anemia Correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of infectious exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: time to complete wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evaluation of rectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Curve (AUC) of Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of symptomatic ICH, major systemic hemorrhage, or other serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: defecate discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evolution in mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Evolution in organ failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution in ICU stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Choice of preferred interface
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic power calculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of different managements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with successful sacral neuromodulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in percentage and level of expression of PD-L1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes